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ABSTRACT

Provided are bis-quaternary ammonium cyclophane compounds which are modulators of nicotinic acetylcholine
receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of
central nervous system disorders, substance use and/or
abuse, and or gastrointestinal tract disorders.

42 Claims, No Drawings
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BIS-QUATERNARY AMMONIUM
CYCLOPHANE COMPOUNDS THAT
INTERACT WITH NEURONAL NICOTINIC
ACETYLCHOLINE RECEPTORS

been estimated that over 90% of [3 H]NIC binding in the
brain is due to association with the heteromeric receptor that
is composed of a4 and ~2 subunits. Also abundant in the
central nervous system are the homomeric receptors labeled
by [3 H]methyllycaconitine (MLA), which has high affinity
for the a7 nicotinic receptor subtype. Nicotinic receptor
subtypes can be studied using functional assays, such as
NIC-evoked neurotransmitter release (e.g., [3 H]dopamine
(DA) release, [3 H]norepinephrine (NE) release, [3 H]serotonin (5-HT) release, [3 H]ganmia-aminobutyric acid
(GABA) release and [3 H]glutamate release) from superfused rat brain slices. Nicotinic receptors are located in the
cell body and terminal areas of these neurotransmitter systerns. NIC facilitates neurotransmitter release from nerve
terminals.
The structural and functional diversity of central nervous
system nicotinic receptors has stimulated a great deal of
interest in developing novel, subtype-selective agonists and/
or antagonists. Some of these agonists are currently being
evaluated in clinical trials for cognitive enhancement and
neuroprotective effects, potentially beneficial for disease
states such as Alzheimer's and Parkinson's disease, as well
as for treatment of drug abuse, depression, obesity and pain
relief.

5

CONTINUING APPLICATION DATA
This application is a continuation of U.S. application Ser.
No. 14/087,643, filed Nov. 22, 2013, which is a divisional of
U.S. application Ser. No. 12/300,197, filed May 18, 2010,
which is a national stage of International Application No.
PCT/US2007/011269, filed May 11, 2007, which claims
benefit of U.S. Provisional Application No. 60/799,881, filed
May 12, 2006, which is incorporated herein by reference in
its entirety.
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IDENTIFICATION OF FEDERAL FUNDING
The present invention was supported by Grant NIH
U19DA017548 from the National Institutes of Health, and
therefore the government may have rights in the invention.
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FIELD OF THE INVENTION
The invention relates to bis-quaternary ammonium cyclophane compounds that interact with neuronal nicotinic
receptors, and to methods of using the compounds to treat
central nervous system diseases and pathologies.

25

BACKGROUND OF THE INVENTION

30

S(-)-Nicotine (NIC) activates presynaptic and postsynaptic neuronal nicotinic receptors that evoke the release of
neurotransmitters from presynaptic terminals and that
modulate the depolarization state of the postsynaptic neuronal membrane, respectively. Thus, nicotine produces its
effect by binding to a family of ligand-gated ion channels,
stimulated by acetylcholine (ACh) or nicotine which causes
the ion channel to open and cations to flux with a resulting
rapid (millisecond) depolarization of the target cell.
Neuronal nicotinic receptors are composed of two types
of subunits, a and ~' and assemble as heteromeric receptors
with the general stoichiometry of 2a and 3~ or as homomeric receptors with 5a subunits. Nine subtypes of the a
subunit (a2 to al0) and three subtypes of the~ unit (~2 to
~4) are found in the central nervous system. The most
common nicotinic receptor subtype in the brain is composed
of two a4 and three ~2 subunits, i.e., a4~2. These subunits
display different, but overlapping, patterns of expression in
the brain. Examples of heteromeric receptor subtypes
include a4~2, a3~2, a3~4, a6~2, a6~2~3, a4a5~2,
a6a5~2, a6a4~2, a6a4~2~3, a4~2~4, a3~2~4, and others. The predominant homomeric subtype includes a7, but
other combinations have also been proposed.
For the most part, the actual subunit compositions and
stoichiometries of nicotinic receptors in the brain remain to
be elucidated. Thus, neuronal nicotinic receptor subtype
diversity originates from differences in the amino acid
sequence at the subunit level and from the multiple combinations of assemblies of subunits into functional receptor
proteins, which affords a wide diversity of pharmacological
specificity.
In spite of the extensive diversity in neuronal nicotinic
receptor messenger RNA expression, only a limited number
of tools are available to study the pharmacology of native
receptors. Radioligands are used in many studies. [3 H]NIC
appears to label the same sites in the brain as [3 H]ACh. It has

SUMMARY OF THE INVENTION
In one embodiment, compounds corresponding to the
following structure are provided.

(I)
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X 18 and X 28 are each independently an organic or
inorganic anion.
Q and Tare each independently attached to R 1 and R 2 . Q
and T are each independently selected from alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl,
substituted arylalkyl, arylalkenyl, substituted arylalkenyl,
arylalkynyl, substituted arylalkynyl, heterocyclic, substituted heterocyclic; SOY 1 , SO 2 Y 1 , SO 2 OY 1 or SO 2 NHY 1 ,
where Y 1 is selected from hydrogen, lower alkyl, alkenyl,
alkynyl or aryl, and where Y 1 is not hydrogen in SOY 1 and
if Y 1 is alkenyl or alkynyl, the site of unsaturation is not
conjugated with a heteroatom; COY2 , where Y 2 is selected
from hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, aryloxy, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl,
arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted
arylalkynyl, heterocyclic, or substituted heterocyclic, and
where ifY2 comprises alkenyl or alkynyl, the site ofunsaturation is not conjugated with the carbonyl group; OY3 ,
where Y 3 is selected from hydrogen, alkyl, substituted alkyl,
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, acyl, alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted heterocyclic, where ifY3 comprises
alkenyl or alkynyl, the site ofunsaturation is not conjugated
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with the oxygen; NY4Ys, where Y 4 and ys are each independently selected from hydrogen, alkyl, substituted alkyl,
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, acyl, alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted heterocyclic, where if Y 4 or ys
comprises alkenyl or alkynyl, the site of unsaturation is not
conjugated with the nitrogen; SY6, where Y 6 is selected
from hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, alkylaryl, substituted
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl,
heterocyclic, or substituted heterocyclic, and where if Y 6
comprises alkenyl or alkynyl, the site of unsaturation is not
conjugated with the sulfur.
R 1 and R 2 are each independently five or six membered
rings as shown in formulas (IIA) and (IIB), wherein each
ring of R 1 and R2 has one, two or three nitrogen atoms, each
ring of R 1 and R 2 has one quatemized nitrogen, and two of
R 3 throughR24 of eachR 1 and two ofR3 throughR24 of each
R 2 are replaced by one attachment to Q and one attachment
to T.

5

10

15

20

25

(IIA)

30

35
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A 1 is carbon or nitrogen, provided that when A 1 joins a
ring atom with an unsaturated bond or is a nitrogen, R 3 is
absent, and when A 1 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 3 and R4 are absent.
A 2 is carbon or nitrogen, provided that when A 2 joins a
ring atom with an unsaturated bond or is a nitrogen, Rs is
absent, and when A 2 joins a ring atom with an unsaturated
bond and is a nitrogen, both Rs and R 6 are absent.
A 3 is carbon or nitrogen, provided that when A 3 joins a
ring atom with an unsaturated bond or is a nitrogen, R 7 is
absent, and when A 3 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 7 and R 8 are absent.
A 4 is carbon or nitrogen, provided that when A 4 joins a
ring atom with an unsaturated bond or is a nitrogen, R 9 is
absent, and when A 4 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 9 and R 10 are absent.
As is carbon or nitrogen, provided that when As joins a
ring atom with an unsaturated bond or is a nitrogen, R 11 is
absent, and when As joins a ring atom with an unsaturated
bond and is a nitrogen, both R 11 and R 12 are absent.
A 6 is carbon or nitrogen, provided that when A 6 joins a
ring atom with an unsaturated bond or is a nitrogen, R 13 is
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absent, and when A 6 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 13 and R 14 are absent.
A 7 is carbon or nitrogen, provided that when A 7 joins a
ring atom with an unsaturated bond or is a nitrogen, R 1s is
absent, and when A 7 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 1s and R 16 are absent.
A 8 is carbon or nitrogen, provided that when A 8 joins a
ring atom with an unsaturated bond or is a nitrogen, R 17 is
absent, and when A 8 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 17 and R 18 are absent.
A 9 is carbon or nitrogen, provided that when A 9 joins a
ring atom with an unsaturated bond or is a nitrogen, R 19 is
absent, and when A 9 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 19 and R 20 are absent.
A 10 is carbon or nitrogen, provided that when A 10 joins a
ring atom with an unsaturated bond or is a nitrogen, R 21 is
absent, and when A 10 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 21 and R 22 are absent.
A 11 is carbon or nitrogen, provided that when A 11 joins a
ring atom with an unsaturated bond or is a nitrogen, R 23 is
absent, and whenA 11 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 23 and R 24 are absent.
R3, R4, Rs, R6, R7, Rs, R9, R10, R11, R12, R13 and R14, or
R1s, R16, R17, R1s, R19, R20, R21, R22, R23 and R24, when
present, are each independently selected from hydrogen,
alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl,
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, heterocyclic, substituted heterocyclic, halo, cyano, nitro; or two adjacent
groups R3 through R 14 , or groups R 1s through R 24 , together
with the atoms to which they are attached on the ring of (IIA)
or (IIB) independently form a three to eight member cyclolkane, substituted cycloalkane, cycloalkene, substituted
cycloalkene, aryl, substituted aryl, heterocycle with one to
three hetero atoms of nitrogen, oxygen or sulfur in the ring,
or substituted heterocycle with one to three hetero atoms of
nitrogen, oxygen or sulfur in the ring; and when all of the
bonds to the ring ammonium nitrogen are saturated, then any
ofR3, R4, Rs, R6, R7, R8, R9, R10, R11, R12, R13, R14, R1s,
R16, R17, R1s, R19, R20, R21, R22, R23 or R24 which is
attached to the ammonium nitrogen is a straight or branched
alkyl group of four carbons or fewer.
In another embodiment, a composition is provided comprising a pharmaceutically acceptable carrier and a compound as described above.
In another embodiment, a method is provided for selectively modulating the function of a nicotinic acetylcholine
receptor comprising administering a therapeutically effective amount of a compound as described above to a mammalian subject in need thereof.
In another embodiment, a method is provided for facilitating transport of a compound of the invention into the
central nervous system by interaction of the compound with
the blood brain barrier choline transporter.
In another embodiment, a method is provided for preventing and/or treating a central nervous system associated
disorder, for example, schizophrenia, Tourettes', Huntington's Chorea, Parkinson's disease, Alzheimer's disease, and
related conditions, comprising administering a therapeutically effective amount of a compound as described above to
a mammalian subject in need thereof.
In another embodiment, a method is provided for preventing and/or treating substance use and/or abuse compris-
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ing administering a therapeutically effective amount of a
compound as described above to a mammalian subject in
need thereof.
In another embodiment, a method is provided for preventing and/or treating gastrointestinal tract disorders comprising administering a therapeutically effective amount of a
compound as described above to a mammalian subject in
need thereof.
Other methods, features and advantages of the present
invention will be or become apparent to one with skill in the
art upon examination of the following detailed descriptions.
It is intended that all such additional methods, features and
advantages be included within this description, be within the
scope of the present invention, and be protected by the
accompanying claims.

The term "central nervous system associated disorders"
includes any cognitive, neurological, and mental disorders
causing aberrant or pathological neural signal transmission,
such as disorders associated with the alteration of normal
neurotransmitter release in the brain.
The term "lower alkyl" refers to straight or branched
chain alkyl radicals having in the range of 1 to 4 carbon
atoms.
The term "alkyl" refers to straight or branched chain alkyl
radicals having 1 to 19 carbon atoms, and "substituted alkyl"
refers to alkyl radicals further bearing one or more substituents including, but not limited to, hydroxy, alkoxy (of a
lower alkyl group), mercapto (of a lower alkyl group), aryl,
heterocyclic, halogen, trifluoromethyl, cyano, nitro, amino,
carboxyl, carbamate, sulfonyl, and sulfonamide.
The term "cycloalkyl" refers to cyclic ring-containing
moieties containing 3 to 8 carbon atoms, and "substituted
cycloalkyl" refers to cycloalkyl moieties further bearing one
or more substituents as set forth above.
The term "alkenyl" refers to straight or branched chain
hydrocarbyl groups having at least one carbon-carbon
double bond and having 2 to 19 carbon atoms, and "substituted alkenyl" refers to alkenyl groups further bearing one or
more substituents as set forth above.
The term "alkynyl" refers to straight or branched chain
hydrocarbyl moieties having at least one carbon-carbon
triple bond and having 2 to 19 carbon atoms, and "substituted alkynyl" refers to alkynyl moieties further bearing one
or more substituents as set forth above.
The term "aryl" refers to aromatic groups having 6 to 24
carbon atoms, and "substituted aryl" refers to aryl groups
further bearing one or more substituents as set forth above.
The term "alkylaryl" refers to alkyl-substituted aryl
groups, and "substituted alkylaryl" refers to alkylaryl groups
further bearing one or more substituents as set forth above.
The term "arylalkyl" refers to aryl-substituted alkyl
groups, and "substituted arylalkyl" refers to arylalkyl groups
further bearing one or more substituents as set forth above.
The term "arylalkenyl" refers to aryl-substituted alkenyl
groups, and "substituted arylalkenyl" refers to arylalkenyl
groups further bearing one or more substituents as set forth
above.
The term "arylalkynyl" refers to aryl-substituted alkynyl
groups, and "substituted arylalkynyl" refers to arylalkynyl
groups further bearing one or more substituents as set forth
above.
The term "heterocyclic" refers to cyclic moieties containing one or more heteroatoms as part of the ring structure and
having 3 to 24 carbon atoms, and "substituted heterocyclic"
refers to heterocyclic moieties further bearing one or more
substituents as set forth above.
The term "acyl" refers to alkyl-carbonyl groups, and
"substituted acyl" refers to acyl groups further bearing one
or more substituents as set forth above.
The term "halogen" refers to fluoride, chloride, bromide
or iodide groups.
It is understood that in all substituted groups defined
above, polymers arrived at by defining substituents with
further substituents to themselves (e.g. substituted aryl having a substituted aryl group as a substituent which is itself
substituted with a substituted aryl group, etc.) are not
intended for inclusion herein. In such cases, the maximum
number of such substituents is three. That is to say that each
of the above definitions is constrained by a limitation that,
for example, substituted aryl groups are limited to -substituted aryl-(substituted aryl)-substituted aryl.
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DETAILED DESCRIPTION OF THE
INVENTION
Before the present compositions and methods are
described, it is to be understood that the invention is not
limited to the particular methodologies, protocols, assays,
and reagents described, as these may vary. It is also to be
understood that the terminology used herein is intended to
describe particular embodiments of the present invention,
and is in no way intended to limit the scope of the present
invention as set forth in the appended claims.
It must be noted that as used herein and in the appended
claims, the singular forms "a," "an," and "the" include plural
references unless the context clearly dictates otherwise.
Unless defined otherwise, all technical and scientific
terms used herein have the same meanings as commonly
understood by one of ordinary skill in the art to which this
invention belongs. All publications cited herein are incorporated herein by reference in their entirety for the purpose
of describing and disclosing the methodologies, reagents,
and tools reported in the publications that might be used in
connection with the invention. Nothing herein is to be
construed as an admission that the invention is not entitled
to antedate such disclosure by virtue of prior invention.
The term "nicotinic acetylcholine receptor" refers to the
endogenous acetylcholine receptor having binding sites for
acetylcholine which also bind to nicotine. The term "nicotinic acetylcholine receptor" includes the term "neuronal
nicotinic acetylcholine receptor."
The terms "subtype of nicotinic acetylcholine receptor,"
and "nicotinic acetylcholine receptor subtype" refer to various subunit combinations of the nicotinic acetylcholine
receptor, and may refer to a particular homomeric or heteromeric complex, or multiple homomeric or heteromeric
complexes.
The term "choline transporter" refers to the endogenous
choline transporter having binding sites for choline which
also bind to positively charged quaternary ammonium
groups. The term "choline transporter" includes the term
"blood brain barrier choline transporter."
The term "agonist" refers to a substance which interacts
with a receptor and increases or prolongs a physiological
response (i.e. activates the receptor).
The term "partial agonist" refers to a substance which
interacts with and activates a receptor to a lesser degree than
an agonist.
The term "antagonist" refers to a substance which interacts with and decreases the extent or duration of a physiological response of that receptor.
The terms "disorder," "disease," and "condition" are used
inclusively and refer to any status deviating from normal.
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Compounds of the present invention are bis-quaternary
ammonium cyclophane compounds corresponding to Formula (I):

(IIA)

(I)

10

X 18 and X 28 are each independently an organic or
inorganic anion.
Q and T are each independently attached to R 1 and R 2. Q
and T are each independently selected from alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl,
substituted arylalkyl, arylalkenyl, substituted arylalkenyl,
arylalkynyl, substituted arylalkynyl, heterocyclic, substituted heterocyclic; SOY1, SO 2Y1, SO 2OY 1 or SO 2NHY 1,
where Y 1 is selected from hydrogen, lower alkyl, alkenyl,
alkynyl or aryl, and where Y 1 is not hydrogen in SOY 1 and
if Y 1 is alkenyl or alkynyl, the site of unsaturation is not
conjugated with a heteroatom; COY2, where Y 2 is selected
from hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkoxy, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, aryloxy, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl,
arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted
arylalkynyl, heterocyclic, or substituted heterocyclic, and
where ifY2 comprises alkenyl or alkynyl, the site ofunsaturation is not conjugated with the carbonyl group; OY3,
where Y 3 is selected from hydrogen, alkyl, substituted alkyl,
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, acyl, alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted heterocyclic, where ifY3 comprises
alkenyl or alkynyl, the site ofunsaturation is not conjugated
with the oxygen; NY4Ys, where Y4 and ys are each independently selected from hydrogen, alkyl, substituted alkyl,
cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl,
alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, acyl, alkylsulfonyl, arylsulfonyl, heterocyclic, or substituted heterocyclic, where if Y4 or ys
comprises alkenyl or alkynyl, the site of unsaturation is not
conjugated with the nitrogen; SY6, where Y 6 is selected
from hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, alkylaryl, substituted
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl,
heterocyclic, or substituted heterocyclic, and where if Y 6
comprises alkenyl or alkynyl, the site of unsaturation is not
conjugated with the sulfur.
R1 and R 2 are each independently five or six membered
rings as shown in formulas (IIA) and (IIB), wherein each
ring of R 1 and R2 has one, two or three nitrogen atoms, each
ring of R 1 and R 2 has one quaternized nitrogen, and two of
R3 throughR24 of eachR 1 and two ofR3 throughR24 of each
R 2 are replaced by one attachment to Q and one attachment
to T.

(IIB)
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A 1 is carbon or nitrogen, provided that when A 1 joins a
ring atom with an unsaturated bond or is a nitrogen, R3 is
absent, and when A 1 joins a ring atom with an unsaturated
bond and is a nitrogen, both R3 and R4 are absent.
A 2 is carbon or nitrogen, provided that when A 2 joins a
ring atom with an unsaturated bond or is a nitrogen, Rs is
absent, and when A 2 joins a ring atom with an unsaturated
bond and is a nitrogen, both Rs and R 6 are absent.
A 3 is carbon or nitrogen, provided that when A 3 joins a
ring atom with an unsaturated bond or is a nitrogen, R7 is
absent, and when A 3 joins a ring atom with an unsaturated
bond and is a nitrogen, both R7 and R 8 are absent.
A4 is carbon or nitrogen, provided that when A 4 joins a
ring atom with an unsaturated bond or is a nitrogen, R9 is
absent, and when A4 joins a ring atom with an unsaturated
bond and is a nitrogen, both R9 and R 10 are absent.
As is carbon or nitrogen, provided that when As joins a
ring atom with an unsaturated bond or is a nitrogen, R 11 is
absent, and when As joins a ring atom with an unsaturated
bond and is a nitrogen, both R 11 and R 12 are absent.
A 6 is carbon or nitrogen, provided that when A 6 joins a
ring atom with an unsaturated bond or is a nitrogen, R 13 is
absent, and when A 6 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 13 and R 14 are absent.
A 7 is carbon or nitrogen, provided that when A 7 joins a
ring atom with an unsaturated bond or is a nitrogen, R 1s is
absent, and when A 7 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 1s and R 16 are absent.
A 8 is carbon or nitrogen, provided that when A 8 joins a
ring atom with an unsaturated bond or is a nitrogen, R 17 is
absent, and when A 8 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 17 and R 18 are absent.
A 9 is carbon or nitrogen, provided that when A 9 joins a
ring atom with an unsaturated bond or is a nitrogen, R 19 is
absent, and when A 9 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 19 and R 20 are absent.
A 10 is carbon or nitrogen, provided that when A 10 joins a
ring atom with an unsaturated bond or is a nitrogen, R 21 is
absent, and when A 10 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 21 and R 22 are absent.
A 11 is carbon or nitrogen, provided that when A 11 joins a
ring atom with an unsaturated bond or is a nitrogen, R 23 is
absent, and whenA 11 joins a ring atom with an unsaturated
bond and is a nitrogen, both R 23 and R 24 are absent.
R3, R4, Rs, R6, R7, Rs, R9, R10, R11, R12, R13 and R14, or
R1s, R16, R17, R1s, R19, R20, R21, R22, R23 and R24, when
present, are each independently selected from hydrogen,
alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl,
alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,
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aryl, substituted aryl, alkylaryl, substituted alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, substituted arylalkenyl, arylalkynyl, substituted arylalkynyl, heterocyclic, substituted heterocyclic, halo, cyano, nitro; or two adjacent
groups R3 through R 14 , or groups R1s through R 24, together
with the atoms to which they are attached on the ring of (IIA)
or (IIB) independently form a three to eight member cyclolkane, substituted cycloalkane, cycloalkene, substituted
cycloalkene, aryl, substituted aryl, heterocycle with one to
three hetero atoms of nitrogen, oxygen or sulfur in the ring,
or substituted heterocycle with one to three hetero atoms of
nitrogen, oxygen or sulfur in the ring; and when all of the
bonds to the ring ammonium nitrogen are saturated, then any
ofR3, R4, Rs, R6, R7, Rs, R9, R10, Ru, R12, R13, R14, R1s,
R16, R17, R1s, R19, R20, R21, R22, R23 or R24 which is
attached to the ammonium nitrogen is a straight or branched
alkyl group of four carbons or fewer.
For example, R 1 and R 2 include pyrrole, pyrrolidine,
pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole, pyridine,
pyrimidine, piperidine, quinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline, pyrazine, piperazine,
pyridazine and triazine.
As another example, R3, R4, Rs, R 6, R7, Rs, R9, R 10 , R 11 ,
R12, R13, R14, R1s, R16, R17, R1s, R19, R20, R21, R22, R23 and
R 24, include hydrogen, methyl, ethyl, propyl, butyl,
hydroxymethyl, hydroxyethyl, hydroxypropyl, trifluoromethyl, chloro, bromo, phenyl, pyrrolidine, N-alkyl pyrrolidine (for example where the alkyl chain is methyl, ethyl or
propyl), unsaturated pyrrolidine, unsaturated N-alkyl pyrrolidine (for example where the alkyl chain is methyl, ethyl or
propyl), aziridine, N-methyl aziridine, azetidine, N-methyl
azetidine, unsaturated azetidine, unsaturated N-methyl azetidine, piperidine, N-methyl piperidine, unsaturated piperidine, unsaturated N-methyl piperidine, azepane, N-methyl
azepane, unsaturated azepane, unsaturated N-methyl
azepane, azocane, N-methyl azocane, unsaturated azocane,
unsaturated N-methyl azocane, l-aza-bicyclo[3.2.1 ]octane,
l-aza-bicyclo[2.2.l]heptane, 8-methyl-8-aza-bicyclo[3.2.1]
octane, l-aza-tricyclo[3.3. l. l 3.7]decane, methyl cycloalkyl,
methyl substituted cycloalkyl, methyl pyrrolidine, methyl
N-alkyl pyrrolidine (for example where the alkyl chain is
methyl, ethyl or propyl), methyl unsaturated pyrrolidine,
methyl unsaturated N-alkyl pyrrolidine (for example where
the alkyl chain is methyl, ethyl or propyl), methyl aziridine,
methyl N-methyl aziridine, methyl azetidine, methyl
N-methyl azetidine, methyl unsaturated azetidine, methyl
unsaturated N-methyl azetidine, methyl piperidine, methyl
N-methyl piperidine, methyl unsaturated piperidine, methyl
unsaturated N-methyl piperidine, methyl azepane, methyl
N-methyl azepane, methyl unsaturated azepane, methyl
unsaturated N-methyl azepane, methyl azocane, methyl
N-methyl azocane, methyl unsaturated azocane, methyl
unsaturated N-methyl azocane, methyl-1-aza-bicyclo[3.2.1]
octane, methy1-1-aza-bicyclo [2 .2 .1 ]heptane, 8-methyl-8aza-bicyclo [3 .2 .1 ]octane,
and
methyl-1-aza-tricyclo
[3.3. l. l 3-7Jdecane.
As a further example, when two adjacent groups R3
through R 14 , or groups R 1s through R 24, together with the
atoms to which they are attached on the ring of (IIA) or (IIB)
independently form a three to eight member cyclolkane,
substituted cycloalkane, cycloalkene, substituted cycloalkene, aryl, substituted aryl, heterocycle with one to three
hetero atoms of nitrogen, oxygen or sulfur in the ring, or
substituted heterocycle with one to three hetero atoms of
nitrogen, oxygen or sulfur in the ring. For example, possible
rings include benzene, pyridine, pyran, indene, isoindene,
benzofuran, isobenzofuran, benzo[b ]thiophene, benzo[ c]

thiophene, indole, indolenine, isoindole, cyclopental[b ]pyridine, pyrano[3,4-b ]pynrole, indazole, indoxazine, benzoxazole, anthranil, naphthalene, tetralin, decalin, chromene,
coumarin, chroman-4-one, isocoumarin, isochromen-3-one,
quinoline, isoquinoline, cinnoline, quinazoline, naphthyrdine, pyrido[3,4-b ]-pyridine, pyridol[3,2-b ]pyridine, pyrido
[4,3,-b ]-pyridine, benzoxazine, anthracene, phenanthrene,
phenalene, fluorene, carazole, xanthene, acnidine, octahydro-[1 ]pyridine, 1-methyloctahydro-[1 ]pyridine, octahydroindole, 1-methyloctahydroindole, octahydro-cyclopenta
[b ]pyrrole,
1-methyloctahydro-cyclopenta[b]pyrrole,
decahydroquinoline, and 1-methyldecahydroquinoline.
X 18 and X 28 , for example, include F-, c1-, Br-, 1-,
NO 2-, HSO4-, SO4-, HPO4-, Po/-, methanesulfonate,
trifluromethane sulfate, p-toluenesulfonate, benzenesulfonate, salicylate, proprionate, ascorbate, aspartate, fumarate, galactarate, maleate, citrate, glutamate, glycolate, lactate, malate, maleate, tartrate, oxalate, succinate, or similar
pharmaceutically acceptable organic acid addition salts,
including the pharmaceutically acceptable salts listed in the
Journal of Pharmaceutical Sciences volume 66, page 2,
1977, which are hereby incorporated by reference. The
above salt forms may be in some cases hydrates or solvates
with alcohols and other solvents.
In a compound of Formula (I), preferably R 1 and R2 are
six-membered, aromatic rings. More preferably, R 1 and R2
are pyridinium rings, such as 1,3-substituted pyridinium
rings.
In a compound of Formula (I), preferably R3 , R4 , Rs, R6 ,
R7, Rs, R9, R10, Ru, R12, R13, R14, R1s, R16, R17, R1s, R19,
R20 , R21 , R22 , R23 or R24 is absent or is hydrogen.
In a compound of Formula (I), preferably Q is attached to
the nitrogen of a pyridinium ring of R 1 and R2. In other
preferred embodiments, Q is attached to the nitrogen of a
pyridinium ring of R 1 and a carbon at the 3-position of a
pyridinium ring ofR2. Preferably, Q is an alkyl group; more
preferably, Q is selected from -(CH 2)4- , -(CH 2) 6- ,
-(CH 2)s-, -(CH 2)9- , -(CH 2) 10- , -(CH 2) 11 - , and
-(CH2)12-In a compound of Formula (I), preferably Tis attached to
the carbon at the 3-position of a pyridinium ring of R 1 and
R2. In other preferred embodiments, T is attached to the
nitrogen of a pyridinium ring of R2 and a carbon at the
3-position of a pyridinium ring of R 1. Preferably, Tis an
alkyl group or a -C C-alkyl-C C- group; more preferably, T is selected from -(CH 2) 12or -C C
-(CH 2) 6-C C-.
In a compound of Formula (I), preferably X 18 and X 28
are halogens. More preferably, X 18 and X 28 are bromide or
iodide.
In another embodiment, the compound of Formula (I) is
defined wherein R 1 and R2 are 1,3-substituted pyridinium
rings, Q is -(CH 2)4- , -(CH 2)6- , -(CH 2)s-,
-(CH 2)9- , -(CH 2) 10- , -(CH 2) 11 - or -(CH 2) 12- , T
is -(CH 2) 12- or ----C C-(CH 2) 6-C C-, and X 1 and
X 2 are bromide or iodide.
Exemplary compounds of the present invention include:
N,N'-(l ,6-hexanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)-bispyridinium diiodide;
N,N'-(l ,8-octananediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)bis-pyridinium diiodide;
N,N'-(l ,9-nonanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)-bispyridinium dibromide;
N,N'-(1, 10-decanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)-bispyridinium diiodide;
N,N'-(1, 11-undecanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)bis-pyridinium dibromide;
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N,N'-(l ,4-butanediyl)-3,3'-(1, 12-dodecanediyl)-bis-pyridinium diiodide;
N,3'-(1, 12-dodecanediyl)-3,N'-(1, 12-dodecanediyl)-bispyridinium dibromide.
The compounds of the present invention may contain one
or more stereocenters. The invention includes all possible
diastereomers and all enantiomeric forms as well as all
combinations of diasteriomers and enantiomers, including
racemic mixtures. The compounds can be separated into
substantially optically pure compounds.
Compounds of the present invention can be prepared, for
example, from corresponding bases by reaction with an
appropriate alkyl bromide.
The compounds of the invention are nicotinic acetylcholine receptor agents. Thus, they may augment or inhibit
3
3
[ H]nicotine binding, [ H]MLA binding, evoke or inhibit
neurotransmitter release, and/or evoke or inhibit the flux of
ions through the nicotinic receptor. Moreover, the compounds of the invention may act either at presynaptic sites or
postsynaptic sites, for example, at a postsynaptic acetylcholine receptor containing an a7 subunit. When acting at a
postsynaptic site, neurotransmitter release per se is not
altered. Rather, the compounds of the invention may act by
interacting with a postsynaptic acetylcholine receptor to
change the membrane potential of the cell, thereby increasing or decreasing the likelihood of firing an action potential.
Alternatively, interaction of a compound of the invention
with a postsynaptic acetylcholine receptor may result in the
alteration of one or more second messenger systems within
the cell so as to decrease or increase the nicotinic cholinergic
response.
In one embodiment, the present invention relates to a
method for selectively modulating the function of a nicotinic
acetylcholine receptor comprising administering to a mammalian subject in need thereof a therapeutically effective
amount of a compound of Formula (I). In such a method, the
compound of Formula (I) may selectively bind to one or
more subtypes ofnicotinic acetylcholine receptor. The compound of Formula (I) may act as an agonist or partial agonist
of nicotinic acetylcholine receptor function. Hence the compound of Formula (I) may increase or prolong the release of
a neurotransmitter from a central nervous system tissue. The
neurotransmitter affected may include dopamine, norepinephrine, serotonin, gannna-aminobutryic acid, or glutamate. Alternatively, the compound of Formula (I) may act as
an antagonist of nicotinic acetylcholine receptor function.
Hence the compound of Formula (I) may decrease the extent
or duration of the release of a neurotransmitter from a central
nervous system tissue. In this regard, the compound of
Formula (I) may act by decreasing stimulant-evoked neurotransmitter release. The neurotransmitter affected may
include dopamine, norepinephrine, serotonin, gamma-aminobutryic acid, or glutamate. Alternatively, the compound of
Formula (I) may act by interacting with a postsynaptic
acetylcholine receptor to change the membrane potential of
the cell thereby increasing or decreasing the likelihood of
firing an action potential, or to alter one or more second
messenger systems within the cell so as to decrease or
increase the nicotinic cholinergic response.
In another embodiment, the present invention is directed
to a method of facilitating transport of a compound of
Formula (I) into the central nervous system by interaction of
the compound with the blood brain barrier choline transporter. Compounds of Formula (I) have high affinity for
blood brain barrier choline transporters and have the potential to be actively transported into the CNS by this transporter. Choline transport at the blood brain barrier is a

sodium-independent, carrier-mediated, and saturable process. The choline transporter binding site contains an anionic
binding area that binds positively charged quaternary ammonium groups. Recent reports have shown that this transporter
is efficacious in delivering quaternary ammonium analogs to
the CNS. The quaternary annnonium structural characteristic of the compounds of Formula (I) provides a unique
synergistic combination of nicotinic receptor interaction and
affinity for the blood brain barrier choline transporter to
maximize transport into the central nervous system.
In another embodiment, the present invention is directed
to a method for preventing and/or treating a central nervous
system associated disorder comprising administering to a
mammalian subject in need thereof a therapeutically effective amount of a compound of Formula (I). In such a
method, the compound of Formula (I) may selectively bind
to one or more subtypes of nicotinic acetylcholine receptor.
The compound of Formula (I) may act as an agonist or
partial agonist of nicotinic acetylcholine receptor function.
Hence the compound of Formula (I) may increase or prolong
the release of a neurotransmitter from a central nervous
system tissue. The neurotransmitter affected may include
dopamine, norepinephrine, serotonin, gannna-aminobutryic
acid, or glutamate. Alternatively, the compound of Formula
(I) may act as an antagonist of nicotinic acetylcholine
receptor function. Hence the compound of Formula (I) may
decrease the extent or duration of the release of a neurotransmitter from a central nervous system tissue. In this regard,
the compound of Formula (I) may act by decreasing stimu!ant-evoked neurotransmitter release. The neurotransmitter
affected may include dopamine, norepinephrine, serotonin,
gannna-aminobutryic acid, or glutamate. Alternatively, the
compound of Formula (I) may act by interacting with a
postsynaptic acetylcholine receptor to change the membrane
potential of the cell thereby increasing or decreasing the
likelihood of firing an action potential, or to alter one or
more second messenger systems within the cell so as to
decrease or increase the nicotinic cholinergic response.
Central nervous system disorders which may be treated
according to the method of the present invention include
Alzheimer's disease, dementia, cognitive dysfunctions (including disorders of attention, focus and concentration),
attention deficit disorders, affective disorders, extrapyramidal motor function disorders, Parkinson's disease, progressive supramolecular palsy, Huntington's disease, Gilles de la
Tourette syndrome, tardive dyskinesia, neuroendocrine disorders, dysregulation of food intake, disorders of nociception, pain, mood and emotional disorders, depression, panic
anxiety, psychosis, schizophrenia, or epilepsy.
In yet another embodiment, the present invention is
directed to a method for preventing and/or treating substance
use and/or abuse comprising administering to a mannnalian
subject in need thereof a therapeutically effective amount of
a compound of Formula (I). In such a method, the compound
of Formula (I) may selectively bind to one or more subtypes
of nicotinic acetylcholine receptor. The compound of Formula (I) may act as an agonist or partial agonist of nicotinic
acetylcholine receptor function. Hence the compound of
Formula (I) may increase or prolong the release of a neurotransmitter from a central nervous system tissue. The
neurotransmitter affected may include dopamine, norepinephrine, serotonin, gamma-aminobutryic acid, or glutamate. Alternatively, the compound of Formula (I) may act as
an antagonist of nicotinic acetylcholine receptor function.
Hence the compound of Formula (I) may decrease the extent
or duration of the release of a neurotransmitter from a central
nervous system tissue. In this regard, the compound of
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Formula (I) may act by decreasing stimulant-evoked neurotransmitter release. The neurotransmitter affected may
include dopamine, norepinephrine, serotonin, gamma-aminobutryic acid, or glutamate. Alternatively, the compound of
Formula (I) may act by interacting with a postsynaptic
acetylcholine receptor to change the membrane potential of
the cell thereby increasing or decreasing the likelihood of
firing an action potential, or to alter one or more second
messenger systems within the cell so as to decrease or
increase the nicotinic cholinergic response.
The conditions of substance use and/or abuse treated
according to the method of the present invention include
nicotine abuse (including use in smoking cessation therapy),
nicotine intoxication, amphetamine abuse, methamphetamine abuse, MDMA (methylenedioxymethamphetamine)
abuse, methylphenidate abuse, cocaine abuse, or alcohol
abuse.
In another embodiment, the present invention is directed
to a method for preventing and/or treating gastrointestinal
tract disorders comprising administering to a manmialian
subject in need thereof a therapeutically effective amount of
a compound of Formula (I). In such a method, the compound
of Formula (I) may selectively bind to one or more subtypes
of nicotinic acetylcholine receptor. The compound of Formula (I) may act as an agonist or partial agonist of nicotinic
acetylcholine receptor function. Hence the compound of
Formula (I) may increase or prolong the release of a neurotransmitter from a central nervous system tissue, or may
increase or prolong the release of a neurotransmitter from a
peripheral nervous system tissue, or may act directly on a
gastrointestinal tract tissue. The neurotransmitter affected
may include dopamine, norepinephrine, serotonin, gammaaminobutryic acid, or glutamate. Alternatively, the compound of Formula (I) may act as an antagonist of nicotinic
acetylcholine receptor function. Hence the compound of
Formula (I) may decrease the extent or duration of the
release of a neurotransmitter from a central nervous system
tissue, or may decrease the extent or duration of the release
of a neurotransmitter from a peripheral nervous system
tissue, or may act directly on a gastrointestinal tract tissue.
In this regard, the compound of Formula (I) may act by
decreasing stimulant-evoked neurotransmitter release. The
neurotransmitter affected may include dopamine, norepinephrine, serotonin, ganmia-aminobutryic acid, or glutamate. Alternatively, the compound of Formula (I) may act by
interacting with a postsynaptic acetylcholine receptor to
change the membrane potential of the cell thereby increasing
or decreasing the likelihood of firing an action potential, or
to alter one or more second messenger systems within the
cell so as to decrease or increase the nicotinic cholinergic
response.
Gastrointestinal disorders which may be treated according
to the method of the present invention include irritable
bowel syndrome, colitis, diarrhea, constipation, gastric acid
secretion or ulcers.
In yet another embodiment, the present invention is
directed to a method for preventing and/or treating inflammatory tract disorders comprising administering to a mammalian subject in need thereof a therapeutically effective
amount of a compound of Formula (I). In such a method, the
compound of Formula (I) may selectively bind to one or
more subtypes ofnicotinic acetylcholine receptor. The compound of Formula (I) may act as an agonist or partial agonist
of nicotinic acetylcholine receptor function. Hence the compound of Formula (I) may increase or prolong the release of
a neurotransmitter from a central nervous system tissue, or
may increase or prolong the release of a neurotransmitter

from a peripheral nervous system tissue, or may act directly
on a non-nervous system tissue. The neurotransmitter
affected may include dopamine, norepinephrine, serotonin,
ganmia-aminobutryic acid, or glutamate. Alternatively, the
compound of Formula (I) may act as an antagonist of
nicotinic acetylcholine receptor function. Hence the compound of Formula (I) may decrease the extent or duration of
the release of a neurotransmitter from a central nervous
system tissue, or may decrease the extent or duration of the
release of a neurotransmitter from a peripheral nervous
system tissue, or may act directly on a non-nervous system
tissue. In this regard, the compound of Formula (I) may act
by decreasing stimulant-evoked neurotransmitter release.
The neurotransmitter affected may include dopamine, norepinephrine, serotonin, gamma-aminobutryic acid, or glutamate. Alternatively, the compound of Formula (I) may act by
interacting with a postsynaptic acetylcholine receptor to
change the membrane potential of the cell thereby increasing
or decreasing the likelihood of firing an action potential, or
to alter one or more second messenger systems within the
cell so as to decrease or increase the nicotinic cholinergic
response.
Inflammatory disorders which may be treated according
to the method of the present invention include adult respiratory distress syndrome, allergy, anemia, ankylosing spondylitis, asthma, atherosclerosis, bacterial infections, benign
prostatic hyperplasia, cholecystitis, ulcerative colitis,
Crohn's disease, diabetes mellitus, emphysema, gastritis,
glomerulonephritis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, osteoarthritis, pancreatitis, polymyositis, psoriasis and rheumatoid arthritis.
The compounds of the present invention can be delivered
directly or in pharmaceutical compositions along with suitable carriers or excipients, as is well known in the art. For
example, a pharmaceutical composition of the invention
may include a conventional additive, such as a stabilizer,
buffer, salt, preservative, filler, flavor enhancer and the like,
as known to those skilled in the art. Exemplary buffers
include phosphates, carbonates, citrates and the like. Exemplary preservatives include EDTA, EGTA, BHA, BHT and
the like.
An effective amount of such agents can readily be determined by routine experimentation, as can the most effective
and convenient route of administration and the most appropriate formulation. Various formulations and drug delivery
systems are available in the art. See, e.g., Gennaro, A. R., ed.
(1995) Remington's Pharmaceutical Sciences.
Suitable routes of administration may, for example,
include oral, rectal, transmucosal, transdermal, topical,
nasal, or intestinal administration and parenteral delivery,
including intramuscular, subcutaneous, intramedullary
injections, as well as intrathecal, direct intraventricular,
intravenous, intraperitoneal, intranasal, or intraocular injections. In addition, the agent or composition thereof may be
administered sublingually or via a spray, including a sublingual tablet or a sublingual spray. The agent or composition thereof may be administered in a local rather than a
systemic marmer. For example, a suitable agent can be
delivered via injection or in a targeted drug delivery system,
such as a depot or sustained release formulation.
The pharmaceutical compositions of the present invention
may be manufactured by any of the methods well-known in
the art, such as by conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes. As noted above,
the compositions of the present invention can include one or
more physiologically acceptable carriers such as excipients
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and auxiliaries that facilitate processing of active molecules
into preparations for pharmaceutical use.
Proper formulation is dependent upon the route of administration chosen. For injection, for example, the composition
may be formulated in aqueous solutions, preferably in
physiologically compatible buffers such as Hanks' solution,
Ringer's solution, or physiological saline buffer. For transmucosal or nasal administration, penetrants appropriate to
the barrier to be permeated are used in the formulation. Such
penetrants are generally known in the art. In a preferred
embodiment of the present invention, the present compounds are prepared in a formulation intended for oral
administration. For oral administration, the compounds can
be formulated readily by combining the active compounds
with pharmaceutically acceptable carriers well known in the
art. Such carriers enable the compounds of the invention to
be formulated as tablets, pills, dragees, capsules, liquids,
gels, syrups, slurries, suspensions and the like, for oral
ingestion by a subject. The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases
such as cocoa butter or other glycerides.
Pharmaceutical preparations for oral use can be obtained
as solid excipients, optionally grinding a resulting mixture,
and processing the mixture of granules, after adding suitable
auxiliaries, if desired, to obtain tablets or dragee cores.
Suitable excipients are, in particular, fillers such as sugars,
including lactose, sucrose, marmitol, or sorbitol; cellulose
preparations such as, for example, maize starch, wheat
starch, rice starch, potato starch, gelatin, gum tragacanth,
methyl cellulose, hydroxypropylmethyl-cellulose, sodium
carboxymethylcellulose,
and/or
polyvinylpyrrolidone
(PVP). If desired, disintegrating agents may be added, such
as the cross-linked polyvinyl pyrrolidone, agar, or alginic
acid or a salt thereof such as sodium alginate. Also, wetting
agents such as sodium dodecyl sulfate may be included.
Dragee cores are provided with suitable coatings. For this
purpose, concentrated sugar solutions may be used, which
may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium
dioxide, lacquer solutions, and suitable organic solvents or
solvent mixtures. Dyestuffs or pigments may be added to the
tablets or dragee coatings for identification or to characterize
different combinations of active compound doses.
Pharmaceutical preparations for oral administration
include push-fit capsules made of gelatin, as well as soft,
sealed capsules made of gelatin and a plasticizer, such as
glycerol or sorbitol. The push-fit capsules can contain the
active ingredients in admixture with filler such as lactose,
binders such as starches, and/or lubricants such as talc or
magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended
in suitable liquids, such as fatty oils, liquid paraffin, or liquid
polyethylene glycols. In addition, stabilizers may be added.
All formulations for oral administration should be in dosages suitable for such administration.
In one embodiment, the compounds of the present invention can be administered transdermally, such as through a
skin patch, or topically. In one aspect, the transdermal or
topical formulations of the present invention can additionally comprise one or multiple penetration enhancers or other
effectors, including agents that enhance migration of the
delivered compound. Transdermal or topical administration
could be preferred, for example, in situations in which
location specific delivery is desired.
For administration by inhalation, the compounds for use
according to the present invention are conveniently deliv-

ered in the form of an aerosol spray presentation from
pressurized packs or a nebulizer, with the use of a suitable
propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or
any other suitable gas. In the case of a pressurized aerosol,
the appropriate dosage unit may be determined by providing
a valve to deliver a metered amount. Capsules and cartridges
of, for example, gelatin, for use in an inhaler or insufllator
may be formulated. These typically contain a powder mix of
the compound and a suitable powder base such as lactose or
starch.
Compositions formulated for parenteral administration by
injection, e.g., by bolus injection or continuous infusion can
be presented in unit dosage form, e.g., in ampoules or in
multi-dose containers, with an added preservative. The
compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may
contain formulatory agents such as suspending, stabilizing
and/or dispersing agents. Formulations for parenteral administration include aqueous solutions or other compositions in
water-soluble form.
Suspensions of the active compounds may also be prepared as appropriate oily injection suspensions. Suitable
lipophilic solvents or vehicles include fatty oils such as
sesame oil and synthetic fatty acid esters, such as ethyl
oleate or triglycerides, or liposomes. Aqueous injection
suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl
cellulose, sorbitol, or dextran. Optionally, the suspension
may also contain suitable stabilizers or agents that increase
the solubility of the compounds to allow for the preparation
of highly concentrated solutions. Alternatively, the active
ingredient may be in powder form for constitution with a
suitable vehicle, e.g., sterile pyrogen-free water, before use.
As mentioned above, the compositions of the present
invention may also be formulated as a depot preparation.
Such long acting formulations may be administered by
implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the
present compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion
in an acceptable oil) or ion exchange resins, or as sparingly
soluble derivatives, for example, as a sparingly soluble salt.
Suitable carriers for the hydrophobic molecules of the
invention are well known in the art and include co-solvent
systems comprising, for example, benzyl alcohol, a nonpolar
surfactant, a water-miscible organic polymer, and an aqueous phase. The co-solvent system may be the VPD cosolvent system. VPD is a solution of3% w/v benzyl alcohol,
8% w/v of the nonpolar surfactant polysorbate 80, and 65%
w/v polyethylene glycol 300, made up to volume in absolute
ethanol. The VPD co-solvent system (VPD:5W) consists of
VPD diluted 1: 1 with a 5% dextrose in water solution. This
co-solvent system is effective in dissolving hydrophobic
compounds and produces low toxicity upon systemic administration. Naturally, the proportions of a co-solvent system
may be varied considerably without destroying its solubility
and toxicity characteristics. Furthermore, the identity of the
co-solvent components may be varied. For example, other
low-toxicity nonpolar surfactants may be used instead of
polysorbate 80, the fraction size of polyethylene glycol may
be varied, other biocompatible polymers may replace polyethylene glycol, e.g., polyvinyl pyrrolidone, and other sugars or polysaccharides may substitute for dextrose.
Alternatively, other delivery systems for hydrophobic
molecules may be employed. Liposomes and emulsions are
well known examples of delivery vehicles or carriers for
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hydrophobic drugs. Liposomal delivery systems are discussed above in the context of gene-delivery systems. Certain organic solvents such as dimethylsulfoxide also may be
employed, although usually at the cost of greater toxicity.
Additionally, the compounds may be delivered using sustained-release systems, such as semi-permeable matrices of
solid hydrophobic polymers containing the effective amount
of the composition to be administered. Various sustainedrelease materials are established and available to those of
skill in the art. Sustained-release capsules may, depending
on their chemical nature, release the compounds for a few
weeks up to over 100 days. Depending on the chemical
nature and the biological stability of the therapeutic reagent,
additional strategies for stabilization may be employed.
For any composition used in the present methods of
treatment, a therapeutically effective dose can be estimated
initially using a variety of techniques well known in the art.
For example, in a cell culture assay, a dose can be formulated in animal models to achieve a circulating concentration
range that includes the IC 50 as determined in cell culture.
Dosage ranges appropriate for human subjects can be determined, for example, using data obtained from cell culture
assays and other animal studies.
A therapeutically effective dose of an agent refers to that
amount of the agent that results in amelioration of symptoms
or a prolongation of survival in a subject. Toxicity and
therapeutic efficacy of such molecules can be determined by
standard pharmaceutical procedures in cell cultures or
experimental animals, e.g., by determining the LD 50 (the
dose lethal to 50% of the population) and the ED 50 (the dose
therapeutically effective in 50% of the population). The dose
ratio of toxic to therapeutic effects is the therapeutic index,
which can be expressed as the ratio LD 50 /ED 50 . Agents that
exhibit high therapeutic indices are preferred.
Dosages preferably fall within a range of circulating
concentrations that includes the ED 50 with little or no
toxicity. Dosages may vary within this range depending
upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration, and dosage should be chosen, according to methods
known in the art, in view of the specifics of a subject's
condition.
The amount of agent or composition administered will, of
course, be dependent on a variety of factors, including the
sex, age, and weight of the subject being treated, the severity
of the affliction, the marmer of administration, and the
judgment of the prescribing physician.
The present compositions may, if desired, be presented in
a pack or dispenser device containing one or more unit
dosage forms containing the active ingredient. Such a pack
or device may, for example, comprise metal or plastic foil,
such as a blister pack. The pack or dispenser device may be
accompanied by instructions for administration. Compositions comprising a compound of the invention formulated in
a compatible pharmaceutical carrier may also be prepared,
placed in an appropriate container, and labeled for treatment
of an indicated condition.
These and other embodiments of the present invention
will readily occur to those of ordinary skill in the art in view
of the disclosure herein, and are specifically contemplated.

intended as illustrations of single aspects of the invention
only. Any methods that are functionally equivalent are
within the scope of the invention. Various modifications of
the invention in addition to those described herein will
become apparent to those skilled in the art from the foregoing description. Such modifications fall within the scope
of the appended claims.
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Example 1
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Preparation of Compound
1, 10-bis-[ (pyridin-3-yl)]-1,9-decadiyne
15

(YBr

pyrrolidine

~--)
20

N

25

30

35

40

45

1,9-Decanediyne (2.8 g, 20.9 mmol) and 3-bromopyridine
(50 mmol) were mixed in pyrrolidine followed by the
addition of Pd(PPh3 ) 2 Cl 2 (50 mg) and Cul (50 mg). The
mixture was heated to 60-70° C. for 2 h. The solvent was
removed in vacuum and the residue was subjected chromatography. Hexane and ethyl acetate 10:1 elute out 3-bromopyridine and 2:1 hexane and ethyl acetate elute out the
product (5.1 g, 85% yield) as oil. HNMR (300 MHz, D 2 0)
8.59 (d, J=l.5 Hz, 2H), 8.43 (dd, J=l.8 Hz, J=5.1 Hz, 2H),
7.62 (dt, J=l.8 Hz, J=7.8 Hz, 2H), 7.15 (ddd, J=0.9 Hz, J=4.8
Hz, J=7.8 Hz, 2H), 2.40 (t, 1=6.9 Hz, 4H), 1.59-1.63 (m,
4H), 1.46-1.49 (m, 4H).
Example 2
Preparation of Compound N,N'-(1,6-hexanediyl)-3,
3'-(1,9-decanediyn-1, 10-diyl)-bis-pyridinium diiodide
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EXAMPLES
The invention is further understood by reference to the
following examples, which are intended to be purely exemplary of the invention. The present invention is not limited
in scope by the exemplified embodiments, which are

Pd(PPh3)2Cl2/Cul

65

$
3,3'-(l,9-Decanediyn-1,10-diyl)-bis-pyridine (1 mmol)
and an equivalent of 1,6-diiodohexane were mixed in
acetonitrile (1000 mL). The mixture was refluxed for 7 days.
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The solvent was removed in vacuum after cooling and the
resulting residue was taken up in water and partitioned
between ethyl ether and water. The aqueous layer was
extracted extensively with ethyl ether remove the starting
materials. Most of the water was removed and the residue
was transferred into methanol. Methanol was removed and
the product was dried under vacuum to afford the bispyridinium cyclophane (30% yield). HNMR (300 MHz,
D 2 0) 8.76 (s, 2H), 8.56 (d, 1=6.0 Hz, 2H), 8.29 (d, 1=8.4 Hz,
2H), 7.81 (dd, 1=6.3 Hz, 8.1 Hz, 2H), 4.40 (t, 1=7.5 Hz, 4H),
2.39 (t, 1=6.3 Hz, 4H), 1.85-1.84 (m, 4H), 1.49-1.52 (m,
4H), 1.38-1.42 (m, 4H), 1.18-1.22 (m, 4H). CNMR, 146.97,
146.26, 142.61, 128.00, 125.71, 101.43, 73.93, 61.99, 29.94,
27.84, 27.49, 24.43, 18.90.

-continued
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Preparation of Compound N,N'-(1,8-octanediyl)-3,
3'-(1,9-decanediyn-1, 10-diyl)-bis-pyridinium diiodide
20

25

3,3'-(l,9-Decanediyn-1,10-diyl)-bis-pyridine (1 mmol)
and an equivalent of 1,9-dibromononane were mixed in
acetonitrile (1000 mL). The mixture was refluxed for 7 days.
The solvent was removed in vacuo after cooling and the
resulting residue was taken up in water and partitioned
between diethyl ether and water. The aqueous layer was
extracted extensively with diethyl ether remove the starting
materials. Most of the water was removed and the residue
was transferred into methanol. Methanol was removed and
the product was dried under vacuum to afford the bispyridinium cyclophane (38% yield) HNMR (300 MHz,
D 2 0) 10.39 (s, 2H), 9.52 (d, 1=5.7, 2H), 8.18 (d, 1=7.5, 8.00
(m, 2H), 5.06 (t, 1=7.2, 4H), 2.49 (t, 1=6.3, 4H), 2.08-2.18
(br, 4H), 1.60-1.80 (br, 12H), 1.42-1.56 (br, SH), 1.37-1.40
(br, 2H).
Example 5

30

Preparation of Compound N,N'-(1,10-decanediyl)-3,
3'-(1,9-decanediyn-1, 10-diyl)-bis-pyridinium diiodide

35

3,3'-(l ,9-Decanediyn-1,10-diyl)-bis-pyridine (1 mmol)
and an equivalent of 1,8-diiodooctane were mixed in
acetonitrile (1000 mL). The mixture was refluxed for 7 days.
The solvent was removed in vacuo after cooling and the
resulting residue was taken up in water and partitioned
between diethyl ether and water. The aqueous layer was
extracted extensively with diethyl ether to remove the starting materials. Most of the water was removed and the
residue was transferred into methanol. Methanol was
removed and dried under vacuum to afford the bis-pyridinium cyclophane (35% yield). HNMR (300 MHz, D 2 0)
10.30 (s, 2H), 9.37 (d, 1=5.7, 2H), 8.19 (d, 1=8.1, 2H), 7.94
(dd, 1=8.1, 1=6.0, 2H), 4.95 (t, 1=8.4, 4H), 2.49 (t, 1=6.6,
4H), 2.14-2.22 (m, 4H), 1.75-1.85 (m, 4H), 1.61-1.68 (m,
SH), 1.54-1.58 (br, SH), 1.49-4.58 (br, 4H).

-45
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Example 4
Preparation of Compound N,N'-(1,9-nonanediyl)-3,
3'-(1,9-decanediyn-1, 10-diyl)-bis-pyridinium di bromide
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3,3'-(l,9-Decanediyn-1,10-diyl)-bis-pyridine (1 mmol)
and an equivalent of 1,10-diiododecane were mixed in
acetonitrile (1000 mL). The mixture was refluxed for 7 days.
The solvent was removed in vacuo after cooling and the
resulting residue was taken up in water and partitioned
between diethyl ether and water. The aqueous layer was
extracted extensively with diethyl ether remove the starting
materials. Most of the water was removed and the residue
was transferred into methanol. Methanol was removed and
the product was dried under vacuum to afford the bispyridinium cyclophane (40% yield). HNMR (300 MHz,
D 2 0), 10.11 (s, 2H), 9.37 (d, 1=6.3, 2H), 8.22 (dt, 1=7.8,
l=l.2, 2H), 8.03 (dd, 1=6.3, 1=7.8, 2H), 4.99 (t, 1=8.1, 4H),
2.49 (t, 1=6.6, 4H), 2.15-2.17 (m, 4H), 1.38-1.75 (m, 24H).
CNMR, 147.73, 145.88, 142.71, 128.04, 126.46, 102.54,
74.29, 61.82, 32.44, 28.71, 27.90, 27.83, 27.40, 25.81,
20.21.
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Example 6

brine (3x40 mL) and saturated brine (40 mL), dried over
anhydrous Na2 SO4 , and concentrated under reduced pressure. The crude product was purified by column chromatography (hexanes:ethylacetate 2: 1 to 1: 1) to afford 3.98 g of
the title compound. Yield: 75%. 1 H NMR (300 MHz,
CDC1 3 ) Ii 1.17-1.40 (m, 16H), 1.53-1.68 (m, 4H), 2.60 (t,
J=7.5 Hz, 4H), 7.20 (dd, J=7.8, 1.8 Hz, 2H), 7.48 (dt, J=7.8,
1.8 Hz, 2H), 8.43 (d, J=5.1 Hz, 2H), 8.44 (s, 2H) ppm; 13 C
NMR (75 MHz, CDC1 3 ) ll 29.4, 29.7, 29.8, 29.9, 31.4, 33.3,
123.3, 135.8, 138.4, 147.2, 150.0 ppm.

Preparation of Compound N,N'-(1,11-undecanediyl)-3,3'-(1,9-decanediyn-1, 10-diyl)-bis-pyridinium dibromide

5

10

Example 8
Preparation of Compound N,N'-(1,4-butanediyl)-3,
3'-(1,12-dodecanediyl)-bis-pyridinium diiodide
15
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3,3'-(l ,9-Decanediyn-1,10-diyl)-bis-pyridine (1 mmol)
and an equivalent of 1,11-dibromoundecane were mixed in
acetonitrile (1000 mL). The mixture was refluxed for 7 days.
The solvent was removed in vacuo after cooling and the
resulting residue was taken up in water and partitioned
between diethyl ether and water. The aqueous layer was
extracted extensively with diethyl ether remove the starting
materials. Most of the water was removed and the residue
was transferred into methanol. Methanol was removed and
the product was dried under vacuum to afford the bispyridinium cyclophane (42% yield). HNMR (300 MHz,
D 2 O), 9.92 (s, 2H), 9.48 (d, J=7.8, 2H), 8.22 (d, J=S.1, 2H),
8.05 (m, 2H), 5.08 (br, 4H), 2.49 (t, J=6.3, 4H), 2.05-2.15
(br, 4H), 1.70-1.82 (br, 12H), 1.55-1.65 (br, 4H), 1.45-1.55
(br, 4H), 1.30-1.45 (SH).
Example 7
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Preparation of Compound
1, 12-bis-(pyridin-3-yl)-dodecane

N
Br
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3,3'-(Dodecan-1,12-diyl)-bis-pyridine (1 mmol) and an
equivalent of 1,4-diiodobutane were mixed in 4-methyl-2pentanol (265 mL). The mixture was refluxed for 28 days.
The solvent was removed in vacuo after cooling and the
resulting residue was taken up in methylene chloride and
water (50 mL, 1: 1). The methylene chloride layer containing
the mono-quaternary ammonium product was removed and
the remaining aqueous layer further extracted with methylene chloride (3x25 mL). The water layer containing the
bis-pyridinium product was evaporated under reduced pressure to low volume (0.5 mL) and transferred into methanol
(5 mL). The methanol was removed and the product was
dried under vacuum to afford the bis-pyridinium cyclophane
(35% yield). 1 H NMR (300 MHz, CD 3 OD) ll 1.21-1.46 (m,
16H), 1.72 (m, 4H), 2.18 (m, 4H), 2.56 (s, 6H), 2.81 (t, J=7.5
Hz, 4H), 4.68 (m, 4H), 8.28 (s, 2H), 8.79 (s, 2H), 8.83 (s,
2H) ppm; 13 C NMR (75 MHz, CD 3 OD) ll 18.8, 28.8, 28.9,
29.4, 29.6, 30.8, 33.5, 61.7, 140.9, 142.3, 143.3, 144.9,
147.6 ppm.

55

Example 9
LDA (2M) (20.40 mL, 40.80 mmol) was added drop-wise
to a solution of 3-picoline (3.80 g, 40.80 mmol) in THF (60
mL) at -78° C. The mixture was stirred for 30 min and then
1,10-dibromodecane (6.43 g, 16.32 mmol) in THF (10 mL)
was added drop-wise. The resulting mixture was warmed to
room temperature and stirred for 4 hrs. Fifty percent saturated NH4 Cl was added to the reaction mixture. The aqueous
phase was extracted with ethylacetate (2x40 mL), and the
combined organic liquors were washed with 50% saturated

--

Preparation of Compound
12-(pyridin-3-yl)-1-bromododecane
60

65u
N

+
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-continued

mM): 2 HEPES, 11.8 NaCl, 0.48 KC!, 0.25 CaCl 2 and 0.12
MgSO4 , pH 7.5. Homogenate was centrifuged (25,000 g, 15
min, 4° C.). Pellets were resuspended in 20 vol buffer and
incubated at 37° C., for 10 min, cooled to 4° C. and
centrifuged (25,000 g, 15 min, 4° C.). Pellets were resuspended and centrifuged using the same conditions. Final
pellets were stored in assay buffer, containing (in mM): 20
HEPES, 118 NaCl, 4.8 KC!, 2.5 CaCl 2 , and 1.2 MgSO4 , pH
7 .5 at - 70° C. Upon use, final pellets were resuspended in
-20 vol assay buffer. Samples (250 µ!) contained 100-140 µg
of membrane protein, 3 nM [3 H]nicotine or 3 nM [3 H]
methyllycaconitine (MLA), and bis-quaternary ammonium
cyclophane analog (100 nM) in assay buffer containing 50
mM Tris. Control was in the absence of analog. In [3 H]
nicotine and [3 H]methyllycaconitine binding assays, nonspecific binding was determined in the presence of 10 µM
cytisine and 10 µM nicotine, respectively. Incubations proceeded for 60 min at room temperature using 96-well plates
and were terminated by harvesting on Unifilter-96 GF/B
filter plates presoaked in 0.5% polyethylenimine, using a
Packard FilterMate harvester. After washing 5 times with
350 µI ice-cold assay buffer, filter plates were dried (60 min,
4° C.), bottom-sealed, and filled with Packard's MicroScint
20 cocktail (40 µI/well). After 60 min, filter plates were
top-sealed, and radioactivity determined using a Packard
TopCount. Protein concentrations were determined using the
Bradford dye-binding procedure bovine serum albumin as
the standard. The results are summarized in Table 1.

Br
5

LDA (2 M) (10.5 mL, 21.22 mmol) was added drop-wise
to a solution of 3-picoline (2.17 g, 23.34 mmol) in THF (60
mL) at -78° C. The mixture was stirred for 30 min and then
1,11-dibromoundecane (10 g, 31.83 mmol) was added in one
portion. The resulting mixture was warmed to 0° C. and
stirred for 4 hrs. Fifty percent saturated NH4 Cl was added to
the reaction mixture. The aqueous phase was extracted with
ethylacetate (2x40 mL), and the combined organic liquors
were washed with 50% saturated brine (3x40 mL) and
saturated brine (40 mL), dried over anhydrous Na 2 SO4 , and
concentrated under reduced pressure. The crude product was
purified by colunm chromatography (hexanes:ethylacetate
4:1) to afford 4.47 g 12-(pyridin-3-yl)-1-bromododecane.
Yield: 59%.
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Example 10
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Preparation of Compound N,3'-(1,12-dodecanediyl)3,N'-(1, 12-dodecanediyl)-bis-pyridinium dibromide
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Example 12
Inhibition of Nicotine-Evoked [3 H]Neurotransmitter
Release Assay

35

40

12-(Pyridin-3-yl)-1-bromododecane was dissolved in
acetonitrile (250 mL). The mixture was refluxed for 24
hours. The solvent was removed in vacuo after cooling and
the resulting residue was taken up by water and diethyl ether
(50 mL, 1:1). The diethyl ether layer containing the starting
material was removed and the remaining aqueous layer
further extracted with diethyl ether (3x25 mL). The water
layer containing the bis-pyridinium product was evaporated
under reduced pressure to low volume (0.5 mL) and transferred into methanol (5 mL). The methanol was removed
and the product was dried under vacuum to afford the
bis-pyridinium cyclophane (25% yield). 1 H NMR (300
MHz, DMSO-d6 ) Ii 1.15-1.39 (m, 32H), 1.63 (m, 4H), 1.90
(m, 4H), 2.78 (t, J=7.8 Hz, 4H), 4.57 (t, J=7.2 Hz, 4H), 8.08
(dd, J=8.1, 6.0 Hz, 2H), 8.48 (d, J=8.1 Hz, 2H), 8.98 (d,
1=6.0 Hz, 2H), 9.10 (s, 2H) ppm; 13 C NMR (75 MHz,
CD 3 OD) Ii 25.5, 28.5, 28.8, 28.9, 29.0, 29.9, 30.7, 31.7,
60.5, 127.4, 142.1, 142.8, 143.8, 144.9 ppm.
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Example 11

[

3

Inhibition of [3 H]nicotine and
H]Methyllycaconitine Binding Assays
65

Whole brain, excluding cortex and cerebellum, was
homogenized in 20 vol of ice-cold buffer, containing (in

Rat striatal slices (500 µm thickness, 6-8 mg wet weight)
were incubated for 30 minutes in Krebs buffer (118 mM
NaCl, 4.7 mM KC!, 1.2 mM MgCl 2 , 1.0 mM NaH 2 PO4 , 1.3
mM CaCl 2 , 11.1 mM glucose, 25 mM NaHCO 3 , 0.11 mM
L-ascorbic acid, and 0.004 mM disodium EDTA; pH 7.4,
and saturated with 95% 0/5% CO 2 ) in a metabolic shaker
at 34 ° C. Slices were rinsed with 15 mL of fresh buffer and
incubated for an additional 30 minutes in fresh buffer
containing 0.1 µM [3 H]dopamine (DA; 6 slices/3 mL).
Subsequently, slices were rinsed with 15 mL of fresh buffer
and transferred to a glass superfusion chamber. Slices were
superfused (1.0 mL/min) for 60 minutes with Krebs buffer
containing nomifensine (10 µM) and pargyline (10 µM) and
maintained at 34° C., pH 7.4, with continual aeration (95%
0 2 /5% CO 2 ). Two five minute samples (5 mL each) were
collected to determine basal outflow of [3 H]DA. The bisquaternary ammonium cyclophane analogs were added to
the superfusion buffer after the collection of the second
sample and remained in the buffer until 12 consecutive five
minute samples were collected. Subsequently, S-( - )-nicotine (10 µM) was added to the buffer and an additional 12
consecutive five minute samples were collected. At the end
of the experiment, each slice was solubilized and the [3 H]
content of the tissue determined.
Radioactivity in the superfusate and tissue samples was
determined by liquid scintillation spectroscopy. Fractional
release for tritium collected in each sample was divided by
the total tritium present in the tissue at the time of sample
collection and was expressed as a percentage of total tritium.
Basal [3 H]outflow was calculated from the average of the
tritium collected in the two five minute samples just before
addition of the quaternary ammonium analog. The sum of
the increase in collected tritium resulting from either expo-

US 9,649,301 B2
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sure to the test compound or exposure to S-(- )-nicotine in
the absence and presence of the test compound equaled total
3
3
[ H]overflow. [ H]Overflow was calculated by subtracting
the [3 H]outflow during an equivalent period of prestimulation from the values in samples collected during and after
drug exposure. Inasmuch as the radiolabelled compounds
were not separated and identified, the tritium collected in
superfusate is referred to as either [3 H]outflow or [3 H]
overflow, rather than as [3 H]DA. [3 H]Overflow primarily
represents [3 H]DA in the presence of nomifensine and
pargyline in the superfusion buffer.
The bis-quaternary ammonium cyclophane analogs were
evaluated for their ability to evoke [3 H]DA release from rat
striatal slices. In addition, the classical competitive nicotinic
antagonist DH~E was also examined in this assay for

comparison. None of the compounds examined had any
significant [3 H]DA releasing properties in this assay in the
concentration range tested.
The bis-quaternary ammonium cyclophane analogs were
also evaluated for their ability to inhibit nicotine evoked
3
[ H]DArelease. In these experiments, the striatal slices were
superfused for 60 minutes with 100 nM concentration of the
bis-quaternary ammonium cyclophane analogs prior to nicotine (10 µM) exposure. Antagonist activity was evaluated by
comparing the nicotine evoked [3 H]overflow in the absence
and presence of the analogs. The relative order of potency of
the bis-quaternary ammonium cyclophane analogs for inhibition of nicotine-evoked [3 H]DA release from rat striatal
slices is illustrated in Table 1.

5
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TABLE 1
Bis-Quaternary Ammonium Cyclophane Compounds: Affinity for the BBB
Choline Transporter, Inhibition of [3 H]Nicotine and [3 H]Methyllycaconitine (MLA) Binding to
Rat Striatal Nicotinic Receptors and Inhibition of Nicotine-evoked [3 H]Dopamine Release from
Superfused Rat Striatal Slices

Inhibition of

Nicotine-

Affinity for the
BBB choline

Inhibition of Inhibition of

evoked

transporter Ki

[3 H]Nicotine

[3 H]MLA

[

COMPOUND

(µM)

bindinga

Bindinl

releasec

Example 2

33.6

7%

2%

ND

Example 3

ND

9%

0%

ND

Example 4

1.4

0%

3%

ND

3

H]DA
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TABLE I-continued

Bis-Quaternary Ammonium Cyclophane Compounds: Affinity for the BBB
Choline Transporter, Inhibition of [3 H]Nicotine and [3 H]Methyllycaconitine (MLA) Binding to
Rat Striatal Nicotinic Receptors and Inhibition of Nicotine-evoked [3 H]Dopamine Release from
Su erfused Rat Striatal Slices

Affinity for the
BBB choline
transporter Ki
(µM)

COMPOUND

Inhibition of
NicotineInhibition of Inhibition of
evoked
3
3
3
[ H]Nicotine
[ H]MLA
[ H]DA
bindinga
Bindingb
releasec

Example 5

0.8

0.55 (Ki,
µM)

4.64 (Ki,
µM)

19%

Example 6

15.2

11%

3%

ND

ND

14 ± 2.6%

3.0 ± 3.0%

23%

2%

0%

20%

N

::::--(f)

Br0

~

Br0

/2

~

N
~(f)

=-

~

~

Example 8

Example 10

aData are% inhibition at 100 nM concentration of the bis-quaternary ammonium cyclophane analogs for at least 1-3 independent experiments; with the exception
of when a Ki value in µMis provided, in which case a full concentration effect was evaluated. Specific binding in the [3H]nicotine binding assay is calculated
as the difference between the total binding of3 nM [3H]nicotinic and nonspecific binding in the presence of 10 µM cold cytisine.
bSpecific binding for the [3H]MLA binding assay is calculated as the difference between the total binding of 2.5 nM [3H]MLA to the receptors alone and its
nonspecific binding in the presence of 1 µM cold nicotine.
cAnalog-induced inhibition of nicotine-evoked [3H]DArelease is calculated as a percent of that in the absence ofbis-quanternary ammonium cyclophane analog.
dND indicates not determined.

It will be appreciated that, although specific embodiments
of the invention have been described herein for purposes of
illustration, various modifications may be made without
departing from the spirit and scope of the invention. All such
modifications and variations are intended to be included

herein within the scope of this disclosure and the present
invention and protected by the following claims.
65

We claim:
1. A method for selectively modulating the function of a
nicotinic acetylcholine receptor comprising administering to
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a mammalian subject in need thereof a therapeutically
effective amount of a compound of Formula (I):

N,N'-(l ,8-octananediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)bis-pyridinium diiodide;
N,N'-(l ,9-nonanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)bis-pyridinium dibromide;
N,N'-(1, 10-decanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)bis-pyridinium diiodide; and
N,N'-(1, 11-undecanediyl)-3,3'-(l ,9-decanediyn-1, 10diyl)-bis-pyridinium dibromide.
11. A method for treating a central nervous system associated disorder comprising administering to a manimalian
subject in need thereof a therapeutically effective amount of
a compound of Formula (I):

(I)

5

wherein X 18 and X 28 are each independently an organic
or inorganic anion;
wherein Q and T are each independently attached to R 1
and R 2 ;
Q is alkyl;
T is alkynyl;
R 1 and R 2 are each six membered rings as shown in
formula (IIA)

10

15

(I)

(IIA) 20

wherein X 18 and X 28 are each independently an organic
or inorganic anion;
wherein Q and T are each independently attached to R 1
and R 2 ;
Q is alkyl;
T is alkynyl;
R 1 and R 2 are each six membered rings as shown m
formula (IIA)

25

wherein R4 is replaced by one attachment to Qin R 1 and
R2;
30
(IIA)
wherein Rs or R 12 is replaced by one attachment to T in
R 1 and R2 ; and
wherein R 6 , Rs, R 10 , R 12 , and R 14 are each independently
selected from hydrogen, lower alkyl, halo, cyano, nitro,
trifluoromethyl, hydroxymethyl, hydroxyethyl, and 35
hydroxypropy I.
2. The method of claim 1, wherein transport of a compound of Formula (I) into the central nervous system is
facilitated by interaction of the compound with the blood
wherein R4 is replaced by one attachment to Qin R 1 and
R2;
brain barrier choline transporter.
40
wherein Rs or R 12 is replaced by one attachment to T in
3. The method of claim 1, wherein the compound of
Formula (I) binds selectively to one or more subtypes of the
R 1 and R 2 ; and
wherein R 6 , Rs, R 10 , R 12 , and R 14 are each independently
nicotinic acetylcholine receptors.
4. The method of claim 3, wherein the selective modulaselected from hydrogen, lower alkyl, halo, cyano, nitro,
tion comprises activation of the function of nicotinic ace- 45
trifluoromethyl, hydroxymethyl, hydroxyethyl, and
hydroxypropyl.
tylcholine receptors as an agonist or as a partial agonist.
5. The method of claim 3, wherein the selective modula12. The method of claim 11, wherein transport of a
tion comprises inactivation of the function of nicotinic
compound of Formula (I) into the central nervous system is
acetylcholine receptors as an antagonist.
facilitated by interaction of the compound with the blood
6. The method of claim 3, wherein there is a decrease in 50 brain barrier choline transporter.
the stimulant-evoked release of a neurotransmitter from a
13. The method of claim 11, wherein the central nervous
central nervous system tissue.
system associated disorder is selected from the group consisting of Alzheimer's disease, dementia, cognitive dysfunc7. The method of claim 3, wherein there is an increase in
the release of a neurotransmitter from a central nervous
tions, attention deficit disorders, affective disorders, extrapy55 ramidal motor function disorders, Parkinson's disease,
system tissue.
progressive supramolecular palsy, Huntington's disease,
8. The method of claim 6, wherein the neurotransmitter
Gilles de la Tourette syndrome, tardive dyskinesia, neuroenreleased is selected from the group consisting of dopamine,
docrine disorders, dysregulation of food intake, disorders of
norepinephrine, serotonin, gamma-aminobutyric acid, and
glutamate.
nociception, pain, mood and emotional disorders, depres9. The method of claim 7, wherein the neurotransmitter 60 sion, panic anxiety, psychosis, schizophrenia, and epilepsy.
released is selected from the group consisting of dopamine,
14. The method of claim 11, wherein the compound of
norepinephrine, serotonin, gamma-aminobutyric acid, and
Formula (I) binds selectively to one or more subtypes of the
glutamate.
nicotinic acetylcholine receptors.
15. The method of claim 14, wherein administering the
10. The method of claim 1, wherein the compound of
Formula (I) is selected from the group consisting of:
65 compound of Formula (I) activates the function of the
N,N'-(l ,6-hexanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)nicotinic acetylcholine receptors as an agonist or as a partial
bis-pyridinium diiodide;
agonist.
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16. The method of claim 14, wherein administering the
23. The method of claim 22, wherein transport of a
compound of Formula (I) into the central nervous system is
compound of Formula (I) inactivates the function of the
facilitated by interaction of the compound with the blood
nicotinic acetylcholine receptors as an antagonist.
brain barrier choline transporter.
17. The method of claim 14, wherein there is a decrease
in the stimulant-evoked release of a neurotransmitter from a 5
24. The method of claim 22 wherein the substance use/
central nervous system tissue.
abuse is selected from the group consisting of nicotine
18. The method of claim 14, wherein there is an increase
abuse, nicotine intoxication, amphetamine abuse, methamin the release of a neurotransmitter from a central nervous
phetamine abuse, MDMA abuse, methylphenidate abuse,
system tissue.
cocaine abuse, and alcohol abuse.
19. The method of claim 17, wherein the neurotransmitter 10
25. The method of claim 22, wherein the compound of
is selected from the group consisting of dopamine, norepiFormula (I) binds selectively to one or more subtypes of the
nephrine, serotonin, gamma-aminobutyric acid, and glutanicotinic acetylcholine receptors.
mate.
26. The method of claim 25, wherein the selective modu20. The method of claim 18, wherein the neurotransmitter
lation comprises activation of the function of nicotinic
is selected from the group consisting of dopamine, norepi- 15 acetylcholine receptors as an agonist or as a partial agonist.
nephrine, serotonin, gamma-aminobutyric acid, and gluta27. The method of claim 25, wherein the selective modumate.
lation comprises inactivation of the function of nicotinic
21. The method of claim 11, wherein the compound of
acetylcholine receptors as an antagonist.
Formula (I) is selected from the group consisting of:
28. The method of claim 25, wherein there is a decrease
20
N,N'-(l ,6-hexanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)in the stimulant-evoked release of a neurotransmitter from a
bis-pyridinium diiodide;
central nervous system tissue.
N,N'-(l ,8-octananediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)29. The method of claim 25, wherein there is an increase
bis-pyridinium diiodide;
in the release of a neurotransmitter from a central nervous
N,N'-(l ,9-nonanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)25 system tissue.
bis-pyridinium dibromide;
N,N'-(1, 10-decanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)30. The method of claim 28, wherein the neurotransmitter
released is selected from the group consisting of dopamine,
bis-pyridinium diiodide; and
N,N'-(1, 11-undecanediyl)-3,3'-(l ,9-decanediyn-1, 10norepinephrine, serotonin, gamma-aminobutyric acid, and
glutamate.
diyl)-bis-pyridinium dibromide.
22. A method for treating substance use and/or abuse 30
31. The method of claim 29, wherein the neurotransmitter
comprising administering to a mammalian subject in need
released is selected from the group consisting of dopamine,
thereof a therapeutically effective amount of a compound of
norepinephrine, serotonin, gamma-aminobutyric acid, and
Formula (I):
glutamate.
32. The method of claim 22, wherein the compound of
35
Formula (I) is selected from the group consisting of:
(I)
N,N'-(l ,6-hexanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)bis-pyridinium diiodide;
N,N'-(l ,8-octananediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)bis-pyridinium diiodide;
40
18
28
N,N'-(l
,9-nonanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)wherein X and X are each independently an organic
bis-pyridinium dibromide;
or inorganic anion;
N,N'-(1, 10-decanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)wherein Q and T are each independently attached to R 1
bis-pyridinium diiodide; and
and R 2 ;
45
Q is alkyl;
N,N'-(1, 11-undecanediyl)-3,3'-(l ,9-decanediyn-1, 10T is alkynyl;
diyl)-bis-pyridinium dibromide.
R 1 and R 2 are each six membered rings as shown in
33. A method for treating gastrointestinal tract disorders
formula (IIA)
comprising administering to a manimalian subject in need
50 thereof a therapeutically effective amount of a compound of
Formula (I):
(IIA)

(I)

55

wherein R4 is replaced by one attachment to Qin R 1 and
R2;
wherein R 8 or R 12 is replaced by one attachment to T in
R 1 and R2 ; and
wherein R 6 , R8, R 10 , R 12 and R 14 are each independently
selected from hydrogen, lower alkyl, halo, cyano, nitro,
trifluoromethyl, hydroxymethyl, hydroxyethyl, and
hydroxypropy I.

60

65

wherein X 18 and X 28 are each independently an organic
or inorganic anion;
wherein Q and T are each independently attached to R 1
and R 2 ;
Q is alkyl;
T is alkynyl;
R 1 and R 2 are each six membered rings as shown m
formula (IIA)
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37. The method of claim 35, wherein the selective modu(IIA)

5

10

wherein R4 is replaced by one attachment to Qin R 1 and
R2;
wherein R 8 or R 12 is replaced by one attachment to T in
R 1 and R2 ; and
wherein R 6 , R8, R 10 , R 12 and R 14 are each independently
selected from hydrogen, lower alkyl, halo, cyano, nitro,
trifluoromethyl, hydroxymethyl, hydroxyethyl, and
hydroxypropy I.
34. The method of claim 33 wherein the gastrointestinal
tract disorder is selected from the group consisting of
irritable bowel syndrome, colitis, diarrhea, constipation,
gastric acid secretion, and ulcers.
35. The method of claim 33, wherein the compound of
Formula (I) binds selectively to one or more subtypes of the
nicotinic acetylcholine receptors.
36. The method of claim 35, wherein the selective modulation comprises activation of the function of nicotinic
acetylcholine receptors as an agonist or as a partial agonist.

15

20

25

lation comprises inactivation of the function of nicotinic
acetylcholine receptors as an antagonist.
38. The method of claim 35, wherein there is a decrease
in the stimulant-evoked release of a neurotransmitter from a
central nervous system tissue.
39. The method of claim 35, wherein there is an increase
in the release of a neurotransmitter from a central nervous
system tissue.
40. The method of claim 38, wherein the neurotransmitter
released is selected from the group consisting of dopamine,
norepinephrine, serotonin, gamma-aminobutyric acid, and
glutamate.
41. The method of claim 39, wherein the neurotransmitter
released is selected from the group consisting of dopamine,
norepinephrine, serotonin, gamma-aminobutyric acid, and
glutamate.
42. The method of claim 33, wherein the compound of
Formula (I) is selected from the group consisting of:
N,N'-(l ,6-hexanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)bis-pyridinium diiodide;
N,N'-(l ,8-octananediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)bis-pyridinium diiodide;
N,N'-(l ,9-nonanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)bis-pyridinium dibromide;
N,N'-(1, 10-decanediyl)-3,3'-(l ,9-decanediyn-1, 10-diyl)bis-pyridinium diiodide; and
N,N'-(1, 11-undecanediyl)-3,3'-(l ,9-decanediyn-1, 10diyl)-bis-pyridinium dibromide.
*
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